Amgen Inc.
KIF18A INHIBITORS
Last updated:
Abstract:
Compounds of formula (I): (I), as defined herein, and synthetic intermediates thereof, which are capable of modulating KIF18A protein thereby influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, including the compounds, and methods of treating disease states related to the activity of KIF18A. ##STR00001##
Status:
Application
Type:
Utility
Filling date:
3 Aug 2020
Issue date:
8 Sep 2022